TENAX THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
TENAX THERAPEUTICS, INC. (TENX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $6.27 per share for the 12-month period ending 2019-12-31, per its 10-K/A filed 2021-04-16.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2021-04-16
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2019-03-31 was $6.27, a 15.68% increase year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2018-03-31 was $5.42, a 697.06% increase year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2017-03-31 was $0.68, a 79.88% decline year-over-year.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2016-03-31 was $3.38.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2019 was $6.27, a 10.78% increase from fiscal 2018.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2018 was $5.66, a 58.38% decline from fiscal 2017.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2017 was $13.60, a 78.27% decline from fiscal 2016.
- TENAX THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2016 was $62.60.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 8 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-12-31 | $6.27 10-K/A · filed 2021-04-16 | |||||
| 2019-09-30 | $6.27 10-Q · filed 2019-11-14 | |||||
| 2019-06-30 | $6.27 10-Q · filed 2019-08-14 | |||||
| 2019-03-31 | $6.27 10-Q · filed 2019-05-15 | |||||
| 2018-12-31 | $5.66 10-K · filed 2020-03-30 | |||||
| 2018-09-30 | $5.66 10-Q · filed 2018-11-14 | |||||
| 2018-06-30 | $5.42 10-Q · filed 2018-08-14 | |||||
| 2018-03-31 | $5.42 10-Q · filed 2018-05-15 | |||||
| 2017-12-31 | $13.60 10-K · filed 2019-04-01 | |||||
| 2017-09-30 | $0.68 10-Q · filed 2017-11-09 | |||||
| 2017-06-30 | $0.68 10-Q · filed 2017-08-09 | |||||
| 2017-03-31 | $0.68 10-Q · filed 2017-05-10 | |||||
| 2016-12-31 | $62.60 10-K · filed 2018-04-02 | $3.13 10-K · filed 2017-03-16 | ||||
| 2016-09-30 | $3.38 10-Q · filed 2016-11-09 | |||||
| 2016-06-30 | $3.37 10-Q · filed 2016-08-09 | |||||
| 2016-03-31 | $3.38 10-Q · filed 2016-05-10 | |||||
| 2015-12-31 | $3.57 10-K · filed 2017-03-16 | |||||
| 2015-10-31 | $3.57 10-Q · filed 2015-12-10 | |||||
| 2015-07-31 | $3.57 10-Q · filed 2015-09-09 | |||||
| 2015-04-30 | $6.95 10-K · filed 2017-03-16 | |||||
| 2015-01-31 | $6.96 10-Q · filed 2015-03-17 | |||||
| 2014-10-31 | $6.97 10-Q · filed 2014-12-15 | |||||
| 2014-07-31 | $6.99 10-Q · filed 2014-09-15 | |||||
| 2014-04-30 | $1.67 10-K · filed 2017-03-16 | |||||
| 2014-01-31 | $1.66 10-Q · filed 2014-03-17 | |||||
| 2013-10-31 | $1.64 10-Q · filed 2013-12-17 | |||||
| 2013-07-31 | $28.82 10-Q · filed 2013-09-17 | |||||
| 2013-04-30 | $36.20 10-KT · filed 2016-03-14 | |||||
| 2013-01-31 | $1.83 10-Q · filed 2013-03-18 | |||||
| 2012-10-31 | $1.85 10-Q · filed 2012-12-14 | |||||
| 2012-07-31 | $1.91 10-Q · filed 2012-09-19 | |||||
| 2012-04-30 | $40.80 10-K · filed 2013-06-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |